Praxis für Physikalische und Rehabilitative Medizin, Mainz-Kostheim, Germany.
Clin Drug Investig. 2004;24(10):559-67. doi: 10.2165/00044011-200424100-00001.
To compare the efficacy and tolerability of dexamethasone-21-palmitate and mepivacaine alone and in combination in the acute treatment of facet syndrome.
A total of 157 patients requiring acute therapy for lumbar facet syndrome were treated with computed tomography (CT)-guided intra-articular infiltration of either an anti-inflammatory corticosteroid, a local anaesthetic or a combination of the two. Patients assigned to the first treatment group (n = 60) received the corticosteroid dexamethasone-21-palmitate (Lipotalon((R))); patients in the second group (n = 36) received the local anaesthetic mepivacaine (Meaverin((R))); patients in the third group (n = 61) received a combination of the two drugs. The study duration was from November 2002 until June 2003.
In all three groups, values for compression pain, stress pain and rest pain improved significantly from baseline within 1 hour of injection: in the dexamethasone monotherapy group there was a 13% reduction in compression pain, 20% reduction in stress, and 22% reduction in rest pain; in the groups that received mepivacaine only or a combination of the two drugs there was a 63% and 60%, respectively, reduction of compression pain, 81% and 83%, respectively, reduction of stress pain, and 84% and 77%, respectively, reduction of rest pain. After 72 hours, improvements in these variables were significantly greater in patients treated with dexamethasone-21-palmitate (either as monotherapy or in combination therapy) than in patients treated with mepivacaine alone. In both groups treated with dexamethasone palmitate there was a 57% and 64%, respectively, reduction of compression pain, 70% and 66%, respectively, reduction of stress pain, and 75% and 64%, respectively, reduction of rest pain. In the mepivacaine monotherapy group there was a 17% reduction in compression pain, 26% reduction in stress pain and 13% reduction in rest pain. Both physicians and patients also rated the dexamethasone-21-palmitate-containing regimens as more effective than mepivacaine alone at 72 hours. Over the entire observation period, combination therapy was, on average, superior to both monotherapy regimens. The proportion of patients using concomitant NSAID medication after 3 days was reduced by 50% in the mepivacaine group and by 76% and 100%, respectively, in the dexamethasone-21-palmitate and combination therapy groups. CT-guided infiltration treatment was well tolerated and was associated with virtually no side effects in this study.
CT-guided infiltration of dexamethasone palmitate, particularly in combination with mepivacaine, represents a safe and effective method for the acute therapy of lumbar facet syndrome. The combination is superior to the local anaesthetic alone with regard to pain reduction up to 3 days after injection.
比较地塞米松-21-棕榈酸酯与甲哌卡因单独和联合应用于急性治疗小关节综合征的疗效和耐受性。
157 例需要腰椎小关节综合征急性治疗的患者接受了计算机断层扫描(CT)引导下关节内注射抗炎皮质类固醇、局部麻醉剂或两者联合治疗。第一治疗组(n=60)患者接受皮质类固醇地塞米松-21-棕榈酸酯(Lipotalon(R))治疗;第二组(n=36)患者接受局部麻醉剂甲哌卡因(Meaverin(R))治疗;第三组(n=61)患者接受两种药物联合治疗。研究时间为 2002 年 11 月至 2003 年 6 月。
在所有三组中,注射后 1 小时内,压缩痛、压力痛和静息痛的数值均较基线显著改善:地塞米松单药治疗组的压缩痛减轻 13%,压力痛减轻 20%,静息痛减轻 22%;仅接受甲哌卡因治疗或两种药物联合治疗的两组的压缩痛分别减轻 63%和 60%,压力痛分别减轻 81%和 83%,静息痛分别减轻 84%和 77%。72 小时后,接受地塞米松-21-棕榈酸酯(无论是单药治疗还是联合治疗)治疗的患者在这些变量方面的改善明显大于接受甲哌卡因单药治疗的患者。接受地塞米松棕榈酸酯治疗的两组患者的压缩痛分别减轻 57%和 64%,压力痛分别减轻 70%和 66%,静息痛分别减轻 75%和 64%。甲哌卡因单药治疗组的压缩痛减轻 17%,压力痛减轻 26%,静息痛减轻 13%。无论是医生还是患者,在 72 小时时都认为含地塞米松-21-棕榈酸酯的方案比甲哌卡因单药治疗更有效。在整个观察期内,联合治疗平均优于两种单药治疗方案。在甲哌卡因组中,接受 NSAID 药物治疗的患者比例在 3 天后减少了 50%,而接受地塞米松-21-棕榈酸酯和联合治疗的患者比例分别减少了 76%和 100%。CT 引导下浸润治疗耐受性良好,在本研究中几乎没有不良反应。
CT 引导下地塞米松棕榈酸酯浸润治疗,特别是与甲哌卡因联合应用,是治疗腰椎小关节综合征的一种安全有效的方法。与单独使用局部麻醉剂相比,在注射后 3 天内,疼痛缓解更明显。